With COVID-19 cases surging in the U.S. and upwards of 65,000 new cases reported on a daily basis, according to Johns Hopkins data, the nation is sorely in need of some good news on the coronavirus front.
Researchers at U.S. biotech giant Moderna delivered some of that welcome news, reporting that the first stage of their COVID-19 vaccine trials provoked an immune response in all 45 participants, Reuters reported.